SpaceStation MRI Receives FDA Clearance

Allows Space® Infusion Pumps to Continuously Deliver Medications Within the MRI Suite

SpaceStation MRI has received 510(k) clearance from the US Food and Drug Administration. The news was announced today by B. Braun Medical.

SpaceStation MRI allows Space® infusion pumps to continuously deliver medications to patients within the MRI suite.

“This clearance allows us to expand our infusion therapy portfolio by providing seamless infusion management across multiple care settings,” said Jonathan Stapley, Director of Marketing for Infusion Systems at B. Braun Medical. “Our Space Infusion System allows standardization of large volume and syringe pumps on the same workflow with one integration,” Stapley continued.

The SpaceStation MRI is designed to shield Space infusion pumps against 1.5-T and 3.0-T magnetic fields to protect the MR scanner and provide interference-free images. Long infusion lines are no longer needed and hospital-wide Space infusion pumps are now able to safely transition patients into the imaging suite with the SpaceStation MRI.

“Clearance of the SpaceStation MRI represents a significant development for patients and healthcare providers,” said Angela Karpf, MD, Corporate Vice President, Medical Affairs at B. Braun Medical. “It will allow patients to be safely transitioned into the MRI suite without the interruption of infusion therapy since there is no need to switch to an alternative pump. The versatility of the SpaceStation MRI accommodates adult, pediatric, and neonatal patients.”

Key features of the SpaceStation MRI include:

  • Each station holds up to 4 Space pumps, including the Infusomat® Space® Large Volume Pump, Perfusor® Space® Syringe Pump, and the Perfusor® PCA Syringe Pump.
  • Integrated TeslaSpy® continuously monitors magnetic field strength to provide proper placement and positioning of the SpaceStation MRI.
  • Pump status window allows for visibility of all infusion pumps with a centralized alarm display to continuously monitor the status on all infusions during imaging.
  • Standard Space infusion lines can be used with the Infusomat Space Large Volume Infusion Pump and non-dedicated disposables are available for the Perfusor Space Syringe Infusion Pump.
  • Full drug library software available with DoseGuard™ (Dose Error Reduction Software) Drug Library Development Software, powered by FDB Infusion Knowledge™ allowing online collaboration, access to FDB reference materials, and customizable drug hard and soft limits.

B. Braun offers a full-line of infusion pumps, drug library management, dose error reduction, and interoperability software. The company has a space efficient design which safely integrates with major EMR systems, asset tracking devices, alarm management technologies, and follows the IHE PCD standards in communication and integration. Their integration solution has been shown to improve IV pump utilization by 167%, resulting in $1M immediate capital savings through reduced inventory requirements1.

B. Braun’s DoseGuard Software is the only drug library development solution available that fully integrates FDB’s Infusion Knowledge Portal2. This provides robust evidence-based drug limits with frequent content updates, collaborative authoring tools, and companion audit trails that enable site administrator customization of drug library records for streamlined upload and incorporation into smart pump software.

In addition, B. Braun offers DoseTrac® Software that provides real-time data for consistent documentation and recognition of issues that may lead to an adverse event. DoseTrac Software and Analysis Service have helped clients achieve up to 100% DL compliance, up to 99% reduction in alerts and significant reduction in infusion related medication errors3.


References

1Versus™ Locating Advantages for Healthcare™: Asset Management Case Study: McLauren Flint, 2017
2
Director of Strategic Alliance, FBD Infusion Knowledge™ (personal communication, October 3, 2018)
3 Vitoux R, Chang H, Lehr J. Establishing benchmarks and identifying opportunities to reduce alert fatigue associated with smart infusion pumps. Poster presentation at the American Society of Health-System Pharmacists Midyear Clinical Meeting, December 2015.

SourceB. Braun

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”